Glaxosmithkline Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 10 Feb 2026
Result Summary
- Glaxosmithkline Pharmaceuticals Ltd reported a 5.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.0%.
- Its expenses for the quarter were up by 4.4% QoQ and 2.2% YoY.
- The net profit increased 14.8% QoQ and increased 28.6% YoY.
- The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 16.54 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1073.38 | 1013.51 | 984.49 | 5.9% | 9.0% |
Total Expenses | 691.43 | 662.15 | 676.39 | 4.4% | 2.2% |
Profit Before Tax | 399.93 | 354.00 | 308.10 | 13.0% | 29.8% |
Tax | 104.31 | 96.51 | 78.22 | 8.1% | 33.4% |
Profit After Tax | 295.62 | 257.49 | 229.88 | 14.8% | 28.6% |
Earnings Per Share | 16.54 | 15.20 | 13.57 | 8.8% | 21.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
GlaxoSmithKline Pharmaceuticals Ltd is a major player in the pharmaceutical industry, primarily involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. These include prescription medicines, vaccines, and over-the-counter healthcare products. The company operates globally, with a significant presence in emerging markets, leveraging its extensive research and development capabilities to innovate and bring new health solutions to the market. Recent major developments in the pharmaceutical industry, such as advancements in biotechnology and personalized medicine, are areas where GlaxoSmithKline Pharmaceuticals Ltd is actively engaged. However, specific recent developments for the company are not available within the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), GlaxoSmithKline Pharmaceuticals Ltd reported a total income of ₹1073.38 crores. This figure represents a 5.9% increase compared to the previous quarter, Q2FY26, where the total income was ₹1013.51 crores. Year-over-year, the total income increased by 9.0% from ₹984.49 crores in Q3FY25. The consistent growth in total income over both the quarterly and annual periods reflects the company's robust revenue-generating capabilities within its operational markets. This growth trajectory is indicative of the company's successful market strategies and product offerings.
Profitability
For Q3FY26, GlaxoSmithKline Pharmaceuticals Ltd achieved a profit before tax of ₹399.93 crores, marking a growth of 13.0% from Q2FY26, which recorded ₹354.00 crores. Compared to Q3FY25, the profit before tax increased by 29.8%, up from ₹308.10 crores. The tax expense for Q3FY26 stood at ₹104.31 crores, reflecting an 8.1% increase from the previous quarter and a substantial 33.4% rise from the same quarter in the previous year. Consequently, the profit after tax for Q3FY26 was ₹295.62 crores, which is a 14.8% increase from Q2FY26 and a 28.6% increase year-over-year from Q3FY25. Earnings per share for the quarter also rose to ₹16.54, up 8.8% from the previous quarter and 21.9% from the previous year, underscoring the company's enhanced profitability and shareholder value.
Operating Metrics
The total expenses for GlaxoSmithKline Pharmaceuticals Ltd in Q3FY26 were ₹691.43 crores, reflecting a 4.4% increase from Q2FY26's ₹662.15 crores and a 2.2% rise year-over-year from ₹676.39 crores in Q3FY25. The company's operational efficiency can be gauged by the relationship between the growth in total income and expenses. The increase in total income outpaced the rise in expenses on both a quarterly and annual basis, contributing to the overall improvement in profitability measures like profit before tax and profit after tax. This performance suggests a favorable operational leverage, where the company's ability to control costs relative to revenue growth is evident. No specific financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio are available in the provided data for further analysis.